Print

Results from the POLO trial: Olaparib may delay cancer progression in metastatic pancreatic cancer patients with BRCA mutations.

https://www.facingourrisk.org/XRAYS/POLO-trial-olaparib-delays-pancreatic-cancer
Full article: www.nejm.org/doi/full/10.1056/NEJMoa1903387

Note: On 12/27/19, the FDA approved olaparib for treatment of pancreatic cancer in people with a BRCA mutation based on the results of the POLO study.

The POLO clinical trial looks at whether the PARP inhibitor olaparib improves outcomes for those with metastatic pancreatic cancer after platinum-based chemotherapy.  (7/3/19) Based on these results 

Expert Guidelines

The National Comprehensive Cancer Network (NCCN) develops guidelines for experts on best practice within cancer care. Newer NCCN guideline recommendations for metastatic pancreatic cancer include that clinicians consider

For metastatic pancreatic cancer patients, modified FOLFIRINOX (fluorouracil [5-FU], leucovorin, irinotecan, oxaliplatin) or gemcitabine/nab-paclitaxel chemotherapy is recommended as a first treatment approach with surgery.

For patients with BRCA1/2  PALB2 mutations, gemcitabine/cisplatin is recommended as a first treatment approach with surgery. Recent recommendtion updates suggest considering olaparib for mainenance therapy for some patients with BRCA mutations and no progression platinum-based chemotherapy.

NCCN suggests tumor testing for patients with metastatic pancreatic cancer for a biomarker known as Microsatellite Instability (MSI). The immunoncology agent pembrolizumab (Keytruda) has been approved to treat patients with advanced cancer who test MSI high.

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following clinical trials are currently recruiting pancreatic cancer patients:

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.